VEGFA and coronary artery disorder: Moreover, CAD is considered to be a risk factor for cardiotoxicity when patients receive systematic VEGF inhibitors, such as bevacizumab and sunitinib25.The intravitreal anti-VEGF agents can access the bloodstream and thus reach detectable levels in the systemic circulation and lead to cardiovascular adverse events26.